Shopping Cart
Remove All
Your shopping cart is currently empty
TSHR antagonist S37a is a selective, orally bioavailable TSHR (thyroid-stimulating hormone receptor) antagonist that inhibits TSH-induced cyclic adenosine monophosphate (cAMP) in TSHR-expressing HEK 293 cells, suitable for studying Graves' orbitopathy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $152 | 6-8 weeks | 6-8 weeks | |
| 5 mg | $378 | 6-8 weeks | 6-8 weeks | |
| 10 mg | $596 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $1,160 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,730 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,530 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $385 | 6-8 weeks | 6-8 weeks |
| Description | TSHR antagonist S37a is a selective, orally bioavailable TSHR (thyroid-stimulating hormone receptor) antagonist that inhibits TSH-induced cyclic adenosine monophosphate (cAMP) in TSHR-expressing HEK 293 cells, suitable for studying Graves' orbitopathy. |
| In vitro | In HEK293 cells, TSHR antagonist S37a exhibits inhibitory activity against TSHR: its IC₅₀ for mTSHR is 40 μM, while the IC₅₀ for hTSHR is approximately 20 μM [1]. TSHR antagonist S37a not only inhibits the activation of TSHR by thyrotropin itself but also suppresses the activation of TSHR by monoclonal TSAbs (including the Homo sapiens-derived antibody M22 and the murine-derived antibody KSAb1) as well as the Broussonetia papyrifera-derived small-molecule agonist C2 [1]. |
| In vivo | The TSHR antagonist S37a can inhibit the cyclic adenosine monophosphate (cAMP) production induced by oligoclonal TSAbs (thyroid-stimulating hormone receptor-stimulating antibodies), and these oligoclonal TSAbs are highly enriched in the serum of patients with Graves' ophthalmopathy (GO) [1]. When administered via oral gavage at a dose of 10 mg/kg, the TSHR antagonist S37a exhibited no toxicity in mice and demonstrated a significant oral bioavailability of 53% [1]. |
| Molecular Weight | 460.57 |
| Formula | C25H20N2O3S2 |
| Cas No. | 2143452-20-2 |
| Relative Density. | 1.54 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (173.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.17 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.